SLC13A3 is a major effector downstream of activated β-catenin in liver cancer pathogenesis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

SLC13A3 is a major effector downstream of activated β-catenin in liver cancer pathogenesis

Published:2024-08-30 Issue:1 Volume:15 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Zhao Wennan,Wang Xue,Han Lifeng,Zhang Chunze,Wang Chenxi,Kong Dexin,Zhang Mingzhe,Xu Tong,Li Gen,Hu Ge,Luo Jiahua,Yee Sook Wah^ORCID,Yang Jia^ORCID,Stahl Andreas^ORCID,Chen Xin^ORCID,Zhang Youcai^ORCID

Funder

National Natural Science Foundation of China

The Key R&D Projects in the Tianjin Science and Technology Pillar Program

Foundation for the National Institutes of Health

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41467-024-51860-2.pdf

Reference55 articles.

1. Faivre, S., Rimassa, L. & Finn, R. S. Molecular therapies for HCC: Looking outside the box. J. Hepatol. 72, 342–352 (2020).

2. Xu, C. et al. Beta-catenin signaling in hepatocellular carcinoma. J. Clin. Invest 132, e154515 (2022).

3. Yamashita, T., Budhu, A., Forgues, M. & Wang, X. W. Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 67, 10831–10839 (2007).

4. Wei, W., Chua, M. S., Grepper, S. & So, S. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo. Int J. Cancer 126, 2426–2436 (2010).

5. Lin, L., Yee, S. W., Kim, R. B. & Giacomini, K. M. SLC transporters as therapeutic targets: emerging opportunities. Nat. Rev. Drug Discov. 14, 543–560 (2015).

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP